Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476210 | 0.90 | BRAF (0.53) | BRAF | |
| SCHEMBL14672307 | 0.88 | BRAF (0.51) | BRAF | |
| SCHEMBL15209295 | 0.87 | BRAF (0.45) | BRAF | |
| SCHEMBL14672323 | 0.86 | BRAF (0.50) | BRAF | |
| SCHEMBL15209685 | 0.85 | BRAF (0.49) | BRAF | |
| SCHEMBL15869617 | 0.84 | BRAF (0.51) | BRAF | |
| SCHEMBL14672379 | 0.83 | BRAF (0.52) | BRAF | |
| SCHEMBL15208379 | 0.82 | BRAF (0.51) | BRAF | |
| SCHEMBL14672581 | 0.81 | BRAF (0.50) | BRAF | |
| SCHEMBL15869706 | 0.81 | BRAF (0.51) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552907-B1 | PYRIDYLTRIAZOLES | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | claimed |
| US-8865703-B2 | Pyridyltriazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | claimed |
| EP-2350052-B1 | ANTIPROLIFERATIVE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | claimed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | claimed |
| US-20130225562-A1 | PYRIDYLTRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2552907-A1 | PYRIDYLTRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2013-02-06 | — | — | EP | claimed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225562-A1 | PYRIDYLTRIAZOLES | CCNT1, CCNT2, MKI67 | BRAF 1435/4885 |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | BRAF 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.